#XBB.1.5 monovalent #vaccine induces lasting cross-reactive responses to #SARS-CoV-2 #variants such as HV.1 and #JN1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific #antibodies, https://etidiohnew.blogspot.com/2025/03/xbb15-monovalent-vaccine-induces.html
Impfaktion am 18.1. 2025 in #berlinmitte
#Comirnaty #JN1 (Alter ab 6 Monate)
und
#Novavax #Nuvaxovid #JN1 (ab 12 Jahren).
Kosten: 15€/Impfling.
Für Voranmeldung Mail-Adresse bei uns erfragen.
Impfung@bildungabersicher.net
[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
Robust antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against a broad range of SARS-CoV-2 Omicron subvariants including JN.1, KP.3.1.1 and XEC
In the case of the JN.1 monovalent mRNA vaccine, we showed that the 50% neutralization titer against XBB.1.5 is greater than that against ancestral B.1.1. This implies that immune imprinting has shifted from pre-Omicron to biased toward Omicron.
#mRNA #Vaccines #XEC #JN1 #KP311
https://www.biorxiv.org/content/10.1101/2024.11.20.624471v1
Neutralizing #Activity and Viral #Escape of #Pemivibart by #SARS-CoV-2 #JN1 #sublineages
Source: BioRxIV, AbstractPemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing…
#SARS-CoV-2 #JN1 reveals attenuated #pathogenicity and #airborne #transmission
Source: BioRxIV, AbstractJN.1 is a subvariant of SARS-CoV-2 Omicron BA.2.86 lineage that was predominant worldwide in early 2024, of which the in vivo characteristics are largely unknown. Our results demonstrated that the replication of JN.1 was more efficient than that of the parental BA.2 in Vero cells, which demonstrated low dependence on TMPRSS2. Compared to Omicron variants BA.2 and XBB…
Evolving #antibody #response to #SARS-CoV-2 #antigenic #shift from #XBB to #JN1
Source: Nature, AbstractThe continuous evolution of SARS-CoV-2, particularly the emergence of BA.2.86/JN.1 lineage replacing XBB, necessitates re-evaluation of vaccine compositions 1–3. Here, we provide a comprehensive analysis of the humoral immune response to XBB and JN.1 human exposure. We demonstrate the antigenic distinctiveness of XBB and JN.1 lineages in SARS-CoV-2-naive individuals,…
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
Novavax updated 2024 booster vaccination received today at Costco in Fremont, California 
"NVX-CoV2705 is an updated version of Novavax's prototype COVID-19 vaccine (NVX-CoV2373) formulated to target the JN.1 variant."
I had Moderna in 2021 (initial & 6-month booster), Pfizer bivalent booster in 2022, and now Novavax monovalent booster in 2023 & 2024 
#Lineage-specific #pathogenicity, immune #evasion, and virological #features of #SARS-CoV-2 #BA286 / #JN1 and #EG51 / HK.3
Source: Nature Communications, AbstractSARS-CoV-2 JN.1 with an additional L455S mutation on spike when compared with its parental variant BA.2.86 has outcompeted all earlier variants to become the dominant circulating variant. Recent studies investigated the immune resistance of SARS-CoV-2 JN.1 but additional factors are speculated to contribute to…
Structural basis for #receptor-binding domain mobility of the #spike in #SARS-CoV-2 #BA286 and #JN1
Source: Nature Communications, AbstractSince 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to…
#Impact of #JN1 #booster #vaccination on #neutralisation of #SARS-CoV-2 variants #KP311 and #XEC
Source: BioRxIV, {Excerpt} Conclusion Collectively, we found that the XEC S protein retains the ability to efficiently engage ACE2 and drive cell entry, although entry into Calu-3 lung cells was reduced. Both KP.3.1.1pp and XECpp were generally less well neutralised compared to JN.1pp, indicating elevated immune evasion. Importantly, JN.1-booster vaccination significantly…
#Human and #hamster #sera correlate well in identifying #antigenic #drift among #SARS-CoV-2 #variants, including #JN1
Source: Journal of Virology, ABSTRACTAntigenic assessments of SARS-CoV-2 variants inform decisions to update COVID-19 vaccines. Primary infection sera are often used for assessments, but such sera are rare due to population immunity from SARS-CoV-2 infections and COVID-19 vaccinations. Here, we show that neutralization titers and breadth of matched…
Immune #escape and attenuated #severity associated with the #SARS-CoV-2 #BA286 / #JN1 #lineage
Source: Nature Communications, AbstractThe SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023–24. However, this surge in infections was not accompanied by COVID-19 hospitalizations and mortality commensurate with prior waves. To understand shifts in COVID-19 epidemiology associated with JN.1…
